Dashboard systems: Implementing pharmacometrics from bench to bedside

AAPS Journal

Volumn 16, Issue 5, 2014, Pages 925-937

  Mould, Diane R ^a   Upton, Richard N ^a,b   Wojciechowski, Jessica ^b  

^a Projections Research Inc   (United States)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Bayes; dashboard; pharmacometrics; population model; therapeutics

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; DIGOXIN; ENOXAPARIN; GENTAMICIN; INFLIXIMAB; METHOTREXATE; VANCOMYCIN;

BAYES THEOREM; BODY SIZE; BODY SURFACE; COMPUTER INTERFACE; COMPUTER PROGRAM; DAS28; DASHBOARD SYSTEM; DOSE CALCULATION; DOSE RESPONSE; DRUG DESIGN PROGRAM; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFLAMMATORY BOWEL DISEASE; PATIENT CARE; PHARMACEUTICAL CARE; PHARMACOLOGICAL SCIENCE; PHARMACOMETRY; POPULATION MODEL; PREDICTION; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; BIOLOGICAL MODEL; COMPUTER ASSISTED DRUG THERAPY; COMPUTER SYSTEM; DECISION SUPPORT SYSTEM; DEVICES; DRUG DEVELOPMENT; DRUG THERAPY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOKINETICS; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; BAYES THEOREM; COMPUTER SYSTEMS; DECISION SUPPORT TECHNIQUES; DRUG DISCOVERY; DRUG DOSAGE CALCULATIONS; DRUG THERAPY; DRUG THERAPY, COMPUTER-ASSISTED; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, BIOLOGICAL; PATIENT SELECTION; PHARMACOGENETICS; PHARMACOKINETICS; RISK ASSESSMENT; RISK FACTORS; SOFTWARE; SOFTWARE DESIGN; SOFTWARE VALIDATION;

EID: 84908356540     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9632-5     Document Type: Review

References (55)

1. Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Mak. 2010;30:328-40.
2. Mould DR, Upton RN. Basic concepts in population modeling, simulation and model based drug development. CPT Pharmacometrics Syst Pharmacol. 2012;26(1):e6.
3. Zineh I, Huang S-M. Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine. Biomark Med. 2011;5:705-13.
4. Barrett JS, Mondick JT, Narayan M, Vijayakumar K, Vijayakumar S. Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. BMC Med Inform Decis Mak. 2008;8:6.
5. Anderson BJ, Holford NH. Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child. 2013;98:737-44.
6. Xu Z, Davis HM, Zhou H. Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther. 2013;137:225-47.
7. Johnson TN, Rostami-Hodjegan A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth. 2011;21:291-301.
8. Xu Z, Mould DR, Hu C, Ford J, Keen M, Davis HM, et al. A population-based pharmacokinetic pooled analysis of infliximab in pediatrics. ACCP National Meeting, San Diego CA; 2012.
9. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33:946-64.
10. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/ Guidances/ucm078932.pdf. Accessed 9 May 2014.
11. Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs. 2010;24:23-39. doi:10.2165/11530560-000000000-00000.
12. Egorin MJ. Horseshoes, hand grenades, and body-surface areabased dosing: aiming for a target. J Clin Oncol. 2003;21:182-3. (Pubitemid 46606144)
13. Ho WR, Germain MJ, Garb J, Picard S, Mackie MK, Bartlett C, et al. Use of 12x/month haemoglobin monitoring with a computer algorithm reduces haemoglobin variability. Nephrol Dial Transplant. 2010;25:2710-4.
14. Miskulin DC, Weiner DE, Tighiouart H, Ladik V, Servilla K, Zager PG, et al. Computerized decision support for EPO dosing in hemodialysis patients. Am J Kidney Dis. 2009;54:1081-8.
15. Dashboard development and data visualization tools for effective BI. http://searchcio.techtarget.com/de fi nition/dashboard. Accessed 3 May 2014.
16. Sivyer A. A dose-rate calculator. Br J Radiol. 1959;32:208-9.
17. Tobler A, Mühlebach S. Intravenous phenytoin: a retrospective analysis of Bayesian forecasting versus conventional dosing in patients. Int J Clin Pharm. 2013;35:790-7. doi:10.1007/s11096-013-9809-5.
18. Felton TW, Roberts JA, Lodise TP, Van Guilder M, Boselli E, Neely MN, et al. Individualization of dosing of piperacillin for critically Ill patients: dosing software to optimize antimicrobial therapy. Antimicrob Agents Chemother. 2014.
19. Wong C, Kumar SS, Graham GG, Begg EJ, Chin PK, Brett J, et al. Comparing dose prediction software used to manage gentamicin dosing. Intern Med J. 2013;43:519-25.
20. García MJ, Gavira R, Santos Buelga D, Dominguez-Gil A. Predictive performance of two phenytoin pharmacokinetic dosing programs from nonsteady state data. Ther Drug Monit. 1994;16:380-7. (Pubitemid 24222522)
21. Mohan M, Batty KT, Cooper JA, Wojnar-Horton RE, Ilett KF. Comparison of gentamicin dose estimates derived from manual calculations, the Australian 'Therapeutic Guidelines: antibiotic' nomogram and the SeBA-GEN and DoseCalc software programs. Br J Clin Pharmacol. 2004;58:521-7. (Pubitemid 39540456)
22. Usman M, Ashraf M, Khokhar MI, et al. Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid fever. Iran J Pharm Res. 2013;12:147-54.
23. Holford SD, Holford NHG, Anderson BJ. Online dose calculation tool for determining dosing regimens in the very young. http://www.paganz.org/sites/ default/ fi les/slides/Admin/ Online%20dose%20calculation%20tool%20for%20determining %20dosing%20regimens%20in%20the%20very%20young.pdf.
24. Mould DR, Moyer B, Amur S, Mukherjee A. The impact of new technologies on the science of clinical care and drug development. AAPS Magazine December. 2013.
25. Papier A. Decision support in dermatology and medicine: history and recent developments. Semin Cutan Med Surg. 2012;31:153-9.
26. Domínguez Hernández KR, Aguilar Lasserre AA, Posada Gómez R, Palet Guzmán JA, González Sánchez BE. Development of an expert system as a diagnostic support of cervical cancer in atypical glandular cells, based on fuzzy logics and image interpretation. Comput Math Methods Med. 2013;2013:796387.
27. Castillo VH, Martínez-García AI, Pulido JRG. A knowledgebased taxonomy of critical factors for adopting electronic health record systems by physicians: a systematic literature review. BMC Med Inform Decis Mak. 2010;10:60-93.
28. Gill J. Bayesian methods: a social and behavioral sciences approach. 2nd ed. Boca Raton: Chapman and Hall; 2008. p. 56-60.
29. Hoeting JA, Madigan D, Raftery AE, Volinsky CT. Bayesian model averaging: a tutorial. Stat Sci. 1999;14:382-417.
30. Mould DR, Frame B. Population pharmacokinetic-pharmacodynamic modeling of biological agents: when modeling meets reality. J Clin Pharmacol. 2010;50(9 Suppl):91S-100.
31. Geweke J, Whiteman C. In: Elliott, Granger, Timmermann, editors. Bayesian forecasting. Handbook of economic forecasting, volume 1 chapter 1. NY: Elsevier; 2006.
32. Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet. 2013;52:9-22.
33. RStudio Inc. Easy web applications in R. 2013. http:// www.rstudio.com/shiny/.
34. Herper M. The truly staggering cost of inventing new drugs. Forbes http://www.forbes.com/sites/matthewherper/2012/02/10/ the-truly-staggering-cost- of-inventing-new-drugs/. Accessed 4 Jul 2012.
35. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711-5. (Pubitemid 39173511)
36. US Department of Health and Human Services, Food and Drug Administration. Critical PathOpportunities. 2006. http://www.fda.gov/ downloads/ ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/UCM077258.pdf. Accessed 5 Jul 2013.
37. Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, et al. Model-based drug development. Clin Pharmacol Ther. 2007;82:21-32. (Pubitemid 46950619)
38. Stone JA, Banfield C, Pfister M, Tannenbaum S, Allerheiligen S, Wetherington JD, et al. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry. J Clin Pharmacol. 2010;50(9 Suppl):20S-30.
39. Jelliffe RW, Schumitzky A, Van Guilder M, Liu M, Hu L, Maire P, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit. 1993;15:380-93. (Pubitemid 23297240)
40. Chow SC, Corey R. Bene fits, challenges and obstacles of adaptive clinical trial designs. Orphanet J Rare Dis. 2011;6:79.
41. FDA Draft Guidance for Industry. Adaptive design clinical trials for drugs and biologics. Rockville: The United State Food and Drug Administration; 2010.
42. Zhang L, Pfister M, Meibohm B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J. 2008;10:552-9.
43. Wetherington JD, Pfister M, Banfield C, Stone JA, Krishna R, Allerheiligen S, et al. Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development. J Clin Pharmacol. 2010;50(9 Suppl):31S-46.
44. Ordas I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in in fl ammatory bowel disease: pharmocokinetics based dosing paradigms. Clin Pharmacol Ther. 2012;91:635-46.
45. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49-54.
46. Ash AS, Ellis RP. Risk-adjusted payment and performance assessment for primary care med care. Med Care. 2012;50:643-53.
47. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70:404-13.
48. O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:1164-70. (Pubitemid 34525821)
49. Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004;50:2072-81. (Pubitemid 38924384)
50. Landewe RB, Boers M, Verhoeven AC, et al . COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46:347-56. (Pubitemid 34136571)
51. Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012;64:2824-35.
52. Proudman SM, Keen HI, Stamp LK, et al. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-in fl ammatory drug use. Semin Arthritis Rheum. 2007;37:99-111. (Pubitemid 350198583)
53. Wojciechowski J, Upton RN, Wiese MD, Foster DJ. Development of a population model of early rheumatoid arthritis disease progression treated with methotrexate, sulfasalazine and hydroxychloroquine. Sydney: Australasian Society for Clinical and Experimental Pharmacology and Toxicology; 2012.
54. Smith GCS, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ. 2003;327:1459-61. (Pubitemid 38045824)
55. Donati F, Miller DR, Fiset P. Target-controlled infusion devices: are we missing much? Can J Anaesth. 2011;58:349 - 53. doi:10.1007/s12630-011-9454-1.